Woman's
Quick facts
Marketed products
- Dexamethasone Mouthwash · Dermatology / Oral Medicine
Dexamethasone is a corticosteroid that suppresses local inflammation and immune responses in the oral cavity when applied topically as a mouthwash.
Phase 3 pipeline
- DAPA/MET XR · Diabetes
DAPA/MET XR is a fixed-dose combination of dapagliflozin (SGLT2 inhibitor) and metformin extended-release that lowers blood glucose by increasing urinary glucose excretion and reducing hepatic glucose production. - EQW plus DAPA · Diabetes
EQW (semaglutide) is a GLP-1 receptor agonist combined with DAPA (dapagliflozin), an SGLT2 inhibitor, to provide dual glucose-lowering effects through incretin mimicry and urinary glucose excretion. - Exenatide once weekly (EQW ) · Diabetes
Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion in response to elevated blood glucose and slows gastric emptying to reduce postprandial glucose levels. - Metformin XR plus liraglutide · Diabetes
Metformin XR reduces hepatic glucose production and improves insulin sensitivity, while liraglutide stimulates insulin secretion and reduces glucagon in a glucose-dependent manner via GLP-1 receptor activation. - Saxagliptin-Metformin XR · Diabetes
Saxagliptin inhibits DPP-4 to increase incretin levels and lower blood glucose, while metformin XR reduces hepatic glucose production and improves insulin sensitivity.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Woman's
What are Woman's's marketed drugs?
Top marketed products include Dexamethasone Mouthwash.
What is Woman's's pipeline?
Woman's has 5 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include DAPA/MET XR, EQW plus DAPA, Exenatide once weekly (EQW ), Metformin XR plus liraglutide.
Related
- Dexamethasone Mouthwash · Dermatology / Oral Medicine
- Sector hub: All tracked pharma companies